Raymond L. Benza
Elite in Hypertension

Dr. Raymond L. Benza

Cardiology
Icahn School Of Medicine At Mount Sinai
1 Gustave L Levy Pl, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Elite in Hypertension
Icahn School Of Medicine At Mount Sinai
1 Gustave L Levy Pl, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Benza is a Cardiologist in New York, New York. Dr. Benza is rated as an Elite provider by MediFind in the treatment of Hypertension. His top areas of expertise are Pulmonary Hypertension, Hypertension, Heart Failure, Heart Transplant, and Aortic Valve Replacement. Dr. Benza is currently accepting new patients.

His clinical research consists of co-authoring 190 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 145 articles and participated in 7 clinical trials in the study of Hypertension.

Specialties
Cardiology
Licenses
Internal Medicine in NY
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1 Gustave L Levy Pl, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Pulmonary Hypertension Association Registry
Pulmonary Hypertension Association Registry
Enrollment Status: Recruiting
Publish Date: July 30, 2025
Hemodynamic-GUIDEd Management of Heart Failure
Hemodynamic-GUIDEd Management of Heart Failure
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Device
Study Phase: Not Applicable
Telemonitoring to Treat Group 2 Pulmonary Hypertension: A Personalized Approach
Telemonitoring to Treat Group 2 Pulmonary Hypertension: A Personalized Approach
Enrollment Status: Withdrawn
Publish Date: June 06, 2023
Intervention Type: Drug
Study Drug: Treprostinil Diolamine
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes
Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

190 Total Publications

TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension.
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension.
Journal: Circulation. Heart failure
Published: September 17, 2025
Similar Doctors
Elite in Hypertension
Dr. Daichi Shimbo
Cardiology
Elite in Hypertension
Dr. Daichi Shimbo
Cardiology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (3.5 miles away)
Languages Spoken:
English
See accepted insurances

Daichi Shimbo is a Cardiologist in New York, New York. Dr. Shimbo is rated as a Distinguished provider by MediFind in the treatment of Hypertension. His top areas of expertise are Hypertension, Atherosclerosis, Coronary Heart Disease, Acute Coronary Syndrome, and Hormone Replacement Therapy (HRT).

Franz H. Messerli
Elite in Hypertension
Dr. Franz H. Messerli
Cardiology
Elite in Hypertension
Dr. Franz H. Messerli
Cardiology
425 W 59th St, 9th Floor, 
New York, NY 
 (2.3 miles away)
212-492-5505
Languages Spoken:
English

Franz Messerli is a Cardiologist in New York, New York. Dr. Messerli is rated as a Distinguished provider by MediFind in the treatment of Hypertension. His top areas of expertise are Hypertension, Hypertensive Heart Disease, Coronary Heart Disease, Heart Bypass Surgery, and Percutaneous Coronary Intervention (PCI).

Deepak L. Bhatt
Elite in Hypertension
Dr. Deepak L. Bhatt
Interventional Cardiology | Cardiology
Elite in Hypertension
Dr. Deepak L. Bhatt
Interventional Cardiology | Cardiology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (0.1 miles away)
212-731-7822
Languages Spoken:
English
See accepted insurances

Deepak Bhatt is an Interventional Cardiologist and a Cardiologist in New York, New York. Dr. Bhatt is rated as an Elite provider by MediFind in the treatment of Hypertension. His top areas of expertise are Heart Attack, Acute Coronary Syndrome, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Benza's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile